The Original Mouthful: McDonald's Australia Revives Legendary Big Mac Chant with a Tech Twist 
Samsung Implements Emergency 6-Day Work Week to Combat Slowing Growth 
Hyundai Halts Advertising on X Amid Antisemitism Row 
Starbucks Revamps Cups to Ease Plastic Waste; New Design to Roll Out in US, Canada 
Samsung Targets Beijing’s EV Semiconductor Market at Auto China 2024 
Polestar to Launch Polestar 4 Pure EV in South Korea 
Coca-Cola Launches Global 'Recycle Me' Campaign to Champion Recycling 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
Canada Set to Enforce OECD Crypto Tax Standards by 2026 
Adidas Ignites Passion with 2024 Athlete Pack Including 49 Footwear Models 
Kawhi Leonard and New Balance Launch the Highly Anticipated KAWHI IV Sneaker 
Sony Pictures, Apollo Global Reportedly In Talks to Jointly Bid for Paramount 
5 Reasons Businesses Can’t Afford Not to Get Fleet Maintenance Software 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
TSMC to Hike Prices for Chips Made Outside Taiwan, Impacting Global Device Costs 
Tesla Dismisses 285 Buffalo, New York Workers in Restructuring Efforts 
LEXINGTON, Mass., April 24, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
